m+Medelevator.RU
← Поиск публикаций
Letters in applied microbiology · 2026

Isolation and Characterization of Lytic Bacteriophages Targeting Clinical Staphylococcus Other Than S. aureus.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Romero-Borja Gerardo Antonio, Jiménez-Camacho Luis Enrique, Sánchez-Herrera Victoria Abigail, Huelgas-Méndez Daniel, Jiménez-Cortes Jesús Guillermo, López-Jácome Luis Esaú, Ortiz-Álvarez Jossue, Franco-Cendejas Rafael, Díaz-Velásquez Clara Estela, Vaca-Paniagua Felipe, Lara-Martínez Reyna, Jiménez-García Luis Felipe, Hussein Fahad Mabood, Khan Altaf, Cadet Frederic, Wood Thomas K, Fernández-Presas Ana María, García-Contreras Rodolfo

Аннотация

Staphylococcus spp., other than S. aureus (SOSA, formerly CoNS), are opportunistic pathogens often linked to biofilm infections on indwelling devices. Their rising antibiotic resistance highlights the need for novel therapies. Bacteriophages are promising due to their specificity and ability to inhibit cell growth and biofilm formation. In this study, lytic phages isolated from swab pools were characterized against six clinical S. epidermidis and S. warneri isolates. Two distinct groups were identified via their host range, transmission electron microscopy, and genome sequencing. Group 1 phage ΘBRJ9 belongs to genus Sepunavirus (Myoviridae), while Group 2 phage ΘBRJ18 belongs to genus Andhravirus (Podoviridae). Both showed rapid adsorption, short latent periods (20 min), and high burst sizes (79 and 60 PFU/cell). They strongly inhibited planktonic SOSA growth at MOI 10, with efficacy comparable to or better than vancomycin, and their genomes lacked lysogeny, virulence, or resistance genes. These phages display a lytic lifestyle and are candidates for targeted SOSA therapies. Future work will assess biofilm efficacy, antibiotic synergies, and in vivo performance.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты